This potency of reduced cell survival was increased in most cancer cell lines when the ATR inhibitor VE-821 was paired with genotoxic agents, especially cisplatin; a significant synergy between VE-821 and cisplatin was also seen within ATM-/p53-deficient cells (61). This evidence concerns the gene TP53 and cancer.